NEW YORK, June 1, 2026, 17:02 (EDT)
PRF Technologies Ltd. (Nasdaq: PRFX) plunged 32.7% to end Monday at $2.02, reversing some of last week’s big jump on its artificial intelligence solar-software pitch. Shares moved in a $1.87 to $2.35 range, with volume topping 3 million. StockAnalysis put the company’s market cap near $1.75 million.
The decline was notable, breaking from the general market trend. SPY and QQQ, both ETFs linked to big U.S. stocks and Nasdaq-type growth names, were a bit higher late Monday.
PRFX dropped after a sharp rally in the thinly traded stock. Benzinga said Monday morning that shares fell on “extreme volatility” as momentum traders had jumped in the previous session after a company update on DeepSolar Predict. Benzinga
PRF said in a May 28 SEC filing that it is getting DeepSolar Predict ready for commercial launch. The platform is built on artificial intelligence, using data patterns to help renewable-energy operators with weather forecasts, power planning, battery storage and market decisions.
Dr. Ehud Geller, chairman at PRF, said renewable operators are handling “financial exposure” with changing power markets. He said the company aims to support customers pushing for “data-driven revenue optimization.”
The company flagged imbalance exposure, or the risk that a power producer delivers a different amount of electricity than it promised to sell. This is a real issue for wind, solar and battery owners if weather shifts fast or grid prices jump.
PRF, based in Tel Aviv, develops reformulated drug candidates like PRF-110 for post-surgical pain, and says its business includes both therapeutics and AI-driven energy optimization. PRF is also known as an energy-software provider.
Heron Therapeutics’ ZYNRELEF is the named comparator on the pharma side. PRF said last week its PRF-110 matched ZYNRELEF in a preclinical pig study, with both showing 72 hours of pain relief. Heron said ZYNRELEF has FDA approval for use in adults to reduce pain for as long as three days after some soft-tissue and orthopedic surgeries.
Geller said the main issue for doctors is if a “new non-opioid therapy can provide sustained pain relief.” But all the company has right now is preclinical data for that head-to-head test. Those data land short of the human trial results most investors want before making up their minds. GlobeNewswire
The risks for PRF remain high. The company flagged going concern issues, ongoing losses, a need for more funding, and relies on drug programs and DeepSolar’s rollout. PRF also needs to maintain its Nasdaq Capital Market spot. According to its annual report, PRF ended 2025 with about $4.1 million in cash and equivalents, booked a net loss of $4.8 million for the year, and carried an accumulated deficit of roughly $61.3 million.
The stock is now set for the next firm update, more than another headline. Traders want actual DeepSolar customer names, launch dates, financing info, or any clinical results. That will say if Monday’s drop was just a shakeout or a major shift after a speculative run.
